.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,118,552

« Back to Dashboard
Patent 7,118,552 protects ZOLADEX and is included in two NDAs.

This patent has forty-seven patent family members in thirty-three countries.

Summary for Patent: 7,118,552

Title:Automatically operable safety shield system for syringes
Abstract:An automatically operable safety shield system for use with a syringe, the safety shield system including an holder having proximal and distal portions and defining an enclosure into which the syringe may be inserted, an outer shield having proximal and distal portions, mounted outwards from the inner holder being axially movable relative to the inner holder between retracted and extended positions, a spring positioned between a first detent on the inner holder and a second detent on the outer shield, and urging the outer shield to its extended position, the inner holder having at least one first opening and the outer shield having at least one first stop member, the first stop member being engageable with the first opening when the outer shield is in the retracted position, the inner holder having distal to the first opening at least one first indentation, the first stop member being engageable with the first indentation when the outer shield is in the extended position.
Inventor(s): Shaw; Derek J. (Macclesfield, GB), Law; Brian R. (Leicester, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:09/936,859
Patent Claim Types:
see list of patent claims
Use;
Patent Metrics:
Source: PatentQuant.com
Field: Medical technology
Back Citations: 253rd percentile
Forward Citations: 16th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca
ZOLADEX
goserelin acetate
IMPLANT;IMPLANTATION019726-001Dec 29, 1989RXYes7,118,552► subscribeY
Astrazeneca
ZOLADEX
goserelin acetate
IMPLANT;IMPLANTATION020578-001Jan 11, 1996RXYes7,118,552► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,118,552

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0003790Feb 18, 2000
PCT Information
PCT FiledFebruary 13, 2001PCT Application Number:PCT/GB01/00590
PCT Publication Date:August 23, 2001PCT Publication Number: WO01/60435

Non-Orange Book Patents for Patent: 7,118,552

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,500,964Automatically operable safety shield system for syringes► subscribe
7,220,247Automatically operable safety shield system for syringes► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,118,552

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovakia11812002► subscribe
Slovenia1259274► subscribe
Russian Federation2234341► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc